Cambridge Investment Research Advisors, Inc. Crispr Therapeutics Ag Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 45,467 shares of CRSP stock, worth $2.99 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
45,467
Previous 39,189
16.02%
Holding current value
$2.99 Million
Previous $1.33 Million
65.82%
% of portfolio
0.01%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding CRSP
# of Institutions
544Shares Held
68.5MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$669 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$368 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$242 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$215 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$187 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.13B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....